Therapeutic niche of Ceftazidime-avibactam

Antibiotic resistance is a major public health problem. Gram-negative infections with multi-resistance are responsible for 700,000 deaths per year. It is estimated that by the year 2050 it could reach figures of up to 10 million deaths per year and become the leading cause of mortality above cardiovascular and oncological diseases. This discouraging outlook has prompted research into new antimicrobials, some of which, such as Ceftazidime-avibactam (CAZ-AVI), have already been introduced into clinical practice. Given its high efficacy and low incidence of adverse effects, it has been approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and ventilator-associated pneumonias. This is a narrative review of the literature covering the main issues related to this antimicrobial, as well as what has been reported so far in our country.

Autorentext

Natalia Muñoz Angulo, médico egresado de la Universidad el Bosque.Daniel Augusto Martin Arsanios, médico egresado de la Universidad de La Sabana, departamento de Medicina interna de la Universidad de La Sabana.Diego Alejandro Cubides Diaz, médico egresado de la Universidad el Bosque, departamento de Medicina interna de la Universidad de La Sabana.